DISCOVER A NEW WAY TO HELP
If you are a healthy male aged between 18 and 50, then you may be eligible to participate in a clinical trial investigating a treatment being developed for a range of different diseases known as autoimmune diseases.
Study Payment ranging from £4290 – £5090.
Plus Travel Expenses
Simbec-Orion Clinical Pharmacology will soon be running a study to investigate a new drug called AX-158.
AX-158 is being developed for the treatment of a range of different diseases which can be broadly categorised as autoimmune and inflammatory diseases. AX-158 is specifically being developed to treat autoimmune and inflammatory diseases such as psoriasis, multiple sclerosis (MS), rheumatoid arthritis and Crohn’s disease.
Currently, there are treatment options available for these conditions; however, these treatments tend to act by blocking the activity of the whole immune system (immunosuppressants) which can leave individuals open to developing infections easily and therefore, there is an unmet need to develop potential new treatments which could be more effective.
The main objectives of this study are as follows:
- To determine the safety and tolerability of AX-158 when it is administered as single and multiple doses at different dose strengths over a period of up to 10 days.
- To investigate the concentration of AX-158 in the blood and urine, how this changes over a period of time and to evaluate whether there are differences in the concentration between different dose strengths over time and between single or multiple doses.
- To investigate the effect of food on the concentration of AX-158 in the blood following administration of AX-158 in both a fasted state (without food) and fed state (following a high-fat breakfast).
This study will be split into 3 separate parts: Part A, B & C. Part A & B is fully recruited. WE ARE NOW RECRUITING FOR PART C
The purpose of Part C is to evaluate the safety, tolerability and concentration of AX-158 in the blood and urine when it is given as a single dose once a day for a period of 10 days (this may be increased to 14 days following Part A data review) at different dose strengths. Part C will consist of 3 planned groups of up to 8 participants in each group: each investigating a different dose strength starting at the lowest dose and gradually increasing in each grou
If you participate in this part of the study, you will be required to stay at the Simbec-Orion clinical unit for a maximum period of 14 days, 13 overnight stays, (this may be increased up to 18 days, 17 overnight stays, following Part A data review) followed by a post study follow-up visit approximately 7 days after the last dose of study drug and you should therefore ensure that you are able to commit to completing all visits before agreeing to participate in the study.
If you complete this part of the study, you will receive a maximum inconvenience payment of £4290
[INCREASE PAYMENT TO £5090 IF DOSING DURATION EXTENDED TO
MAXIMUM 14 DAY PERIOD].
We also pay additional travel expenses for every visit.
Thank you for your time to register your interest in this trial please complete the below form.